Skip to main content

Targeted Alpha Therapy Radiation Safety

By Troy Zhou, PhD, DABR, DABSNM
• 17 min read

Introduction

Targeted alpha therapy (TAT) turns the usual radiation safety intuition on its head: the external dose rate from an alpha emitter is low, but the internal hazard from even a small contamination event is severe. A radiation safety program built around the thick-lead, keep-your-distance habits of high-energy gamma work will protect against the wrong thing. For actinium-225, lead-212, and the other alpha emitters now entering routine clinical use, the controlling risks are contamination, intake, bioassay, body-fluid handling, and waste — not structural shielding. 1, 4

The reason is physics. Alpha particles carry a few MeV but travel only tens of microns in tissue and are stopped by a sheet of paper or the dead outer layer of skin, so they contribute almost nothing to external dose. 1 That same high linear energy transfer (LET) is exactly what makes them therapeutically powerful — and what makes an internal uptake dangerous. The relative biological effectiveness of Ac-225 compared with the beta emitter Lu-177 has been estimated at roughly 2 and higher once DNA repair is considered, and radiation protection weights alpha radiation 20 times more heavily than photons or electrons. 5, 12 A speck of inhaled or ingested alpha-emitting material therefore matters far more than its modest external reading would suggest.

This guide explains how to build a defensible radiation safety program for a TAT clinic: the decay physics that drives the hazard, alpha-aware contamination control and surveys, bioassay and internal monitoring, waste and the actinium-227 impurity problem, patient and body-fluid precautions, and the emerging-use licensing framework. It complements our shielding-focused RPT shielding guide and our alpha-emitter dosimetry and microdosimetry discussion. DRPS supports radiopharmaceutical therapy programs across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Topic Explanation

What TAT is and why it is growing

Targeted alpha therapy couples an alpha-emitting radionuclide to a targeting vector — a small molecule such as a PSMA ligand, a peptide, or an antibody — so the alpha emission is delivered directly to tumor cells. 1, 2 The clearest clinical momentum is in metastatic castration-resistant prostate cancer, where Ac-225-PSMA-617 and related agents have shown meaningful prostate-specific antigen responses in heavily pretreated patients, with hematologic effects among the notable toxicities. 2, 3 As these therapies move from specialized centers into broader practice, more radiation safety officers and medical physicists will need to run alpha-capable programs. 1

The alpha emitters of TAT

Several radionuclides anchor current and emerging TAT, and their safety profiles differ in the details that matter for a program.

Radionuclide Approx. half-life Alpha emissions Notable daughter photons for detection Safety note
Actinium-225 ~9.9 days 4 net alphas in the decay chain Francium-221 (~218 keV), bismuth-213 (~440 keV) Daughter recoil/redistribution; possible Ac-227 impurity 4, 13
Lead-212 (→ bismuth-212) ~10.6 hours Alpha via Bi-212/Po-212 branch Pb-212 (~239 keV) Short-lived in-vivo alpha generator; 239 keV aids surveys 1
Radium-223 dichloride ~11.4 days 4 net alphas in the decay chain Low-yield photons (~80–270 keV range) Approved bone-seeking agent; body-fluid precautions 1
Astatine-211 ~7.2 hours 1 alpha (branching) ~79 keV polonium X-rays Volatility is a handling concern 1

Each entry is a starting point; the exact decay data, yields, and any impurities must be confirmed from authoritative nuclear data for the specific product in use. 13

The inverted hazard

The defining feature of TAT radiation safety is the inversion of the external-versus-internal balance. For a gamma emitter, external dose drives the program. For an alpha emitter, external dose is a secondary concern and internal contamination is the primary one. 1, 4 This single idea reorganizes everything downstream: the instruments you buy, the surveys you run, the bioassay you schedule, the way you handle spills and body fluids, and how you think about waste.

Key Technical Principles

External dose is real but modest

Although alphas do not escape the source, Ac-225's decay chain produces photon-emitting daughters, so there is a measurable external field near vials, syringes, waste, and treated patients. 4 A point-source estimate uses the specific gamma-ray (air-kerma or ambient dose) constant :

Published radiation-protection work gives an Ac-225-with-daughters constant on the order of . 7 For a prepared dose of at :

and at 1 m it falls to about 3.5 µSv/h. Those are manageable numbers that justify localized vial and syringe shielding and sensible time-and-distance practice, but not the heavy structural barriers a therapy gamma source would demand. 4, 7 This is why TAT shielding is usually a localized, workflow problem rather than a wall problem.

Internal dose is the dominant hazard

The contrast appears the moment material gets inside the body. Equivalent dose weights the absorbed dose by the radiation weighting factor:

So an internal absorbed dose of just from alpha radiation to a tissue delivers an equivalent dose of:

twenty times what the same absorbed dose of gamma or beta radiation would imply. 12 The biological picture is even starker at the cellular level, where the high-LET track structure of Ac-225 yields a relative biological effectiveness greater than that of Lu-177. 5 This is the quantitative core of the inverted hazard: external readings stay low, but an intake is heavily penalized. Preventing intake — not blocking external photons — is the program's first job.

Daughter recoil and redistribution

Ac-225 adds a complication beyond ordinary contamination. When a daughter atom is created by alpha decay, the recoil energy can break it free of the chelator, so free francium-221 and bismuth-213 can redistribute in the body and in the environment rather than staying with the targeting molecule. 1, 4 For radiation safety, this means the hazard is not a single fixed species but a small decay chain, and both surveys and waste assessments should consider the daughters, not just the parent. 4

Alpha contamination is hard to see

Because alpha particles travel only a short distance in air and are absorbed by the thinnest covering, routine thin-window GM pancake probes and sodium-iodide survey meters cannot be relied on to find alpha surface contamination. 1, 4 Dedicated alpha-sensitive instruments — gas-proportional or zinc-sulfide (ZnS) scintillation detectors — and wipe tests counted by alpha or liquid-scintillation counting are required. The daughter photons of Ac-225 (around 218 and 440 keV) do give a gamma signature that a scintillation detector can use for gross localization, which is useful but does not substitute for proper alpha contamination monitoring. 4

Clinical Impact

Bioassay and internal monitoring

Because intake is the controlling risk, bioassay is not optional in a TAT program — it is central, and it is analytically demanding. Routine internal-exposure monitoring aims to detect effective doses at the level of about 1 mSv per year, and for a short-lived multi-emission radionuclide like Ac-225 that target is hard to reach with a single conventional measurement. Published work shows that combining measurements — summing alpha and gamma spectra and exploiting the radionuclide's several emissions — can bring the detectable annual effective dose for Ac-225 down to roughly 1 mSv, whereas a conventional separate evaluation might only detect on the order of 90 mSv. 6 The practical message is that bioassay frequency, method, and detection limits must be designed deliberately with the measurement physics in mind, ideally before the first patient is treated. For the broader framework, see our discussion of internal dose assessment and bioassay.

Contamination events and body fluids

A TAT program must plan for the contamination and spill scenarios that dominate its risk, including drug handling, blood, urine, and other excreta that carry alpha-emitting material and its daughters. 1 Controls parallel those for other alpha and high-contamination work: gloves and protective clothing, absorbent coverings, dedicated preparation areas, meticulous technique, alpha-aware surveys after every procedure, and defined spill-response steps. The emphasis on body-fluid precautions is the same lesson that applies to approved alpha agents such as radium-223, where contamination control, not shielding, governs. 1 Our notes on radioactive material spill response and contamination monitoring and frisking apply directly, with the caveat that instrumentation must be alpha-capable.

Waste and the actinium-227 problem

Short-lived TAT radionuclides invite decay-in-storage. With a roughly 10-day half-life, Ac-225 decays by a factor of about 1000 in ten half-lives (around 99 days), following with . 13 But a major caveat applies: the Ac-225 supply produced by some routes can contain a long-lived actinium-227 impurity (half-life about 21.8 years), which does not decay away on a decay-in-storage timescale and can carry annual-limit-on-intake, waste-classification, and even decommissioning financial-assurance implications. 4 Waste planning must therefore account for both the intended therapeutic radionuclide and any long-lived contaminant, and the license should reflect that reality. See radioactive waste management in nuclear medicine for the baseline framework.

Patient release

The low external dose rate makes external release of TAT patients comparatively straightforward on a dose-rate basis, but the release conversation cannot stop at the survey meter. Patients excrete alpha-emitting material, so written instructions on hygiene, body-fluid handling, and contamination precautions — and caregiver guidance — are an essential part of release for alpha therapy, as they are for other radiopharmaceutical therapies. 1 The principles in our patient release after radiopharmaceutical therapy guide carry over, with the alpha-specific emphasis on contamination rather than external exposure.

Practical Optimization Tips

A workable TAT radiation safety program follows a consistent arc.

1. Reframe the hazard for staff

Train everyone that external readings will look reassuringly low and that this is precisely why contamination discipline matters. The habits that protect against alpha hazard are hand hygiene, glove discipline, surveys, and bioassay — not standing farther back. 1, 4

2. Buy the right instruments

Equip the program with alpha-sensitive survey instruments (gas-proportional or ZnS scintillation) and an alpha or liquid-scintillation counting capability for wipe tests, in addition to the gamma instruments used for daughter-photon localization. 4

3. Engineer the workspace

Use dedicated, well-characterized preparation areas with absorbent, removable coverings, local vial and syringe shielding for the daughter photons, and contained waste pathways. Localized shielding addresses the modest external field without overbuilding. 4, 7

4. Design bioassay before you treat

Set the bioassay method, baseline, frequency, and detection limits with the measurement physics in mind, using combined-measurement approaches where needed to reach a defensible detection level. 6

5. Plan waste around the longest-lived component

Base decay-in-storage and release decisions on the full radionuclide inventory, explicitly including any Ac-227 or other long-lived impurity, and document the assay basis. 4

6. Make release instructions contamination-centered

Give patients and caregivers clear, written body-fluid and hygiene precautions, not just an external dose-rate reading. 1

Common pitfalls to avoid

  • Running an alpha program with gamma instruments. Thin-window GM and NaI meters will not reliably find alpha contamination. 4
  • Treating bioassay as routine. For Ac-225, reaching a meaningful detection limit takes deliberate method design. 6
  • Forgetting the daughters. Recoil can free francium-221 and bismuth-213, changing both contamination and dose. 1, 4
  • Assuming short half-life solves waste. A long-lived Ac-227 impurity can defeat simple decay-in-storage. 4
  • Over-shielding walls while under-controlling contamination. The dominant risk is internal, not external. 1

Regulatory Considerations

Alpha-therapy radiopharmaceuticals are byproduct material, and a U.S. program must be built on the facility's radioactive material license and the rules that govern medical use of byproduct material. The protection standards and the medical-use framework both apply, and the emerging status of many agents shapes how they are licensed.

Key frameworks to document against:

  • 10 CFR Part 20 — Standards for Protection Against Radiation, including occupational and public dose limits, the annual-limit-on-intake and derived-air-concentration framework that is central to an internal-hazard program, surveys, posting, and waste provisions. 9
  • 10 CFR Part 35 — Medical Use of Byproduct Material, including the radiation safety officer and authorized user structure, instrumentation, written directives, recordkeeping, and patient release. 10
  • 10 CFR 35.1000 (other medical uses) — the emerging-use pathway under which many TAT agents that are not specifically addressed elsewhere are licensed, supported by NRC or Agreement State guidance; see our overview of 10 CFR 35.1000 emerging medical uses. 10
  • NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including surveys, instruments, and procedures, which a TAT program must satisfy with alpha-capable methods. 11
  • Regulatory guidance specific to alpha emitters — published analyses highlight alpha contamination monitoring expectations, annual-limit-on-intake considerations, and decommissioning financial assurance where long-lived impurities such as Ac-227 are present. 4

Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that administer their own medical-use programs, while Washington, DC and Delaware are regulated directly by the NRC. Because most TAT agents are clinical or investigational drugs, the program must also confirm FDA status (including any investigational new drug requirements) for the specific product. A facility should verify which authority issues its license and which intake, survey, and reporting requirements apply before relying on any assumption. This work connects to radioactive material license support, radiation safety officer consulting, and radiation safety training.

Frequently Asked Questions (FAQs)

What is targeted alpha therapy (TAT)?

Targeted alpha therapy delivers an alpha-emitting radionuclide — such as actinium-225, lead-212/bismuth-212, radium-223, or astatine-211 — to tumor cells using a targeting molecule like a PSMA ligand or antibody. Alpha particles deposit very high energy over a few cell diameters, which makes TAT biologically potent but also changes how the radiation safety program must be designed.

Why is radiation safety for alpha emitters different from beta emitters like Lu-177?

Alpha particles travel only microns and are stopped by the skin's outer layer, so the external dose rate from an alpha-therapy source is low. The hazard shifts almost entirely to internal contamination: if alpha-emitting material is inhaled, ingested, or absorbed through a wound, its high linear energy transfer makes even tiny intakes consequential. The program emphasizes contamination control and bioassay rather than structural shielding.

Does Ac-225 require heavy shielding?

Usually no major structural shielding is needed for the alpha emission itself, but Ac-225 has radioactive daughters — including francium-221 and bismuth-213 — that emit photons, so localized shielding of vials, syringes, and waste and a modest external-dose assessment are still warranted. The dominant safety effort is contamination control, not thick barriers.

How do you detect alpha contamination in a TAT program?

Alpha particles have too short a range to be reliably detected by common thin-window GM or sodium iodide survey meters, so alpha contamination requires alpha-sensitive instruments (gas-proportional or zinc-sulfide scintillation detectors) and wipe tests counted by alpha or liquid-scintillation counting. The daughter photons of Ac-225 can also provide a usable gamma signature for surveys, but they do not replace dedicated alpha contamination monitoring.

Why is bioassay so important and so difficult for Ac-225?

Because internal uptake is the dominant hazard, monitoring workers for internal contamination is essential — but detecting an effective dose at the regulatory level of interest is analytically demanding. Published work shows that combining alpha and gamma spectrometry measurements can lower the detectable annual effective dose for Ac-225 to roughly 1 mSv, where a conventional single-measurement evaluation might only reach about 90 mSv. Bioassay design must be deliberate, not an afterthought.

How is TAT waste managed?

Short-lived alpha-therapy radionuclides such as Ac-225 (about a 10-day half-life) are candidates for decay-in-storage, but the common Ac-225 supply can contain a long-lived actinium-227 impurity that does not decay away on that timescale, which complicates storage and release and can carry decommissioning and financial-assurance implications. Waste handling must account for both the therapeutic radionuclide and any long-lived contaminants.

What regulations govern a U.S. TAT program?

Alpha-therapy radiopharmaceuticals are byproduct material regulated under 10 CFR Part 20 (protection standards, surveys, intake limits) and 10 CFR Part 35 (medical use). Because many TAT agents are not specifically listed, their medical use is typically licensed under the emerging-use pathway of 10 CFR 35.1000 with NRC or Agreement State guidance, and clinical agents are also FDA-regulated. The specifics must be confirmed with the licensing authority.

Key Takeaways

  • TAT inverts the radiation safety problem: alpha emission keeps external dose rates low, so internal contamination control, not structural shielding, is the priority. 1, 4
  • Internal dose is heavily penalized — alpha radiation carries a weighting factor of 20 and a relative biological effectiveness greater than Lu-177 — so preventing intake is the program's first job. 5, 12
  • Alpha contamination needs alpha-capable instruments; routine GM and NaI meters are not sufficient, though Ac-225 daughter photons aid gross localization. 4
  • Bioassay is central and analytically hard; combined-measurement methods can reach about 1 mSv detectable annual effective dose for Ac-225. 6
  • Waste planning must include long-lived impurities such as Ac-227, which can defeat simple decay-in-storage. 4
  • Document the program against 10 CFR Part 20 and Part 35, typically licensing emerging agents under 35.1000, and confirm FDA and Agreement State requirements. 9, 10, 11

Conclusion

Targeted alpha therapy is one of the most promising directions in nuclear medicine, and it asks radiation safety programs to unlearn a reflex. The alpha emitters that make these therapies effective are quiet on a survey meter held at arm's length and loud inside the body. A program that spends its energy on lead walls and keeps only a casual eye on contamination and bioassay will have optimized the wrong variable. The defensible approach is the opposite: alpha-aware surveys and instruments, deliberately designed bioassay, contamination-centered procedures and patient instructions, waste planning that respects long-lived impurities, and licensing under the emerging-use framework with the full radionuclide inventory in view. Get that reframing right, and a facility can bring alpha therapy to its patients safely, confidently, and in a way that will stand up to inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services helps radiopharmaceutical therapy programs build alpha-capable radiation safety from the ground up. This can include program and procedure design for Ac-225 and Pb-212 agents, instrument selection and contamination-survey methods, bioassay and internal-monitoring program design, waste and decay-in-storage planning that accounts for long-lived impurities, patient-release and body-fluid precaution instructions, and license and RSO support aligned with NRC and Agreement State requirements through our radioactive material license support, radiation safety officer, and radiation safety training services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Alpha therapy rewards programs that plan for the hazard that does not show up on the survey meter.

Related Resources

References

  1. Morgenstern A, Apostolidis C, Kratochwil C, et al. An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11(3):200-208. doi:10.2174/1874471011666180502104524. PubMed
  2. De Vincentis G, Gerritsen W, Gschwend JE, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019;30(11):1728-1739. doi:10.1093/annonc/mdz270. PubMed
  3. Ninatti G, Scilipoti P, Pini C, et al. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer — a systematic review and meta-analysis. Theranostics. 2025;15(8):3386-3399. doi:10.7150/thno.106574. PubMed
  4. Shober M. Regulating alpha-emitting radioisotopes and specific considerations for actinium-225 containing actinium-227. Appl Radiat Isot. 2022;187:110337. doi:10.1016/j.apradiso.2022.110337. PubMed
  5. Rumiantcev M, Li WB, Lindner S, et al. Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy. EJNMMI Phys. 2023;10(1):53. doi:10.1186/s40658-023-00567-2. PubMed
  6. Meisenberg O. Reduction of detection limits in monitoring of internal exposures by a combined evaluation of emissions and spectra. Radiat Environ Biophys. 2024;63(3):371-383. doi:10.1007/s00411-024-01079-y. PubMed
  7. Marengo M, Infantino A. Assessment of emission data and transmission factors supporting radiation protection in the use of 225Ac. Physica Medica. 2022;103:59-65. doi:10.1016/j.ejmp.2022.10.007. doi.org
  8. Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Physics. 2012;102(3):271-291. doi:10.1097/HP.0b013e318235153a. PubMed
  9. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
  10. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material (including 35.1000 Other Medical Uses). ecfr.gov
  11. U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Program-Specific Guidance About Medical Use Licenses. nrc.gov
  12. International Commission on Radiological Protection. ICRP Publication 103: The 2007 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP. 2007;37(2-4). icrp.org
  13. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org